Nivolumab‐associated extragenital lichen sclerosus et atrophicus
Clinical and Experimental Dermatology2019Vol. 45(3), pp. 350–352
Citations Over TimeTop 17% of 2019 papers
Nicola di Meo, Claudio Conforti, Paola Corneli, Roberta Vezzoni, Chiara Retrosi, Maria Antonietta Pizzichetta, G Rizzi, Iris Zalaudek
Abstract
Recently the first case of genital lichen sclerosus (LS) involving the vulval, perineal and perianal areas during treatment with Nivolumab was published1 . Nivolumab is a human monoclonal antibody, approved by the US Food and Drug Administration (FDA) in December 2014 for the treatment of metastatic melanoma (MM)2 . It works by inhibiting the interaction between programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance.
Related Papers
- → Interleucinas na encefalopatia hipóxico-isquêmica(2003)14 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)